184 related articles for article (PubMed ID: 19404482)
1. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.
Chandalia A; Clarke HJ; Clemens LE; Pandey B; Vicena V; Lee P; Lavan BE; Gregoire FM
PPAR Res; 2009; 2009():706852. PubMed ID: 19404482
[TBL] [Abstract][Full Text] [Related]
2. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
[TBL] [Abstract][Full Text] [Related]
3. Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist.
Clarke HJ; Gregoire F; Ma F; Martin R; Zhao S; Lavan BE
PPAR Res; 2008; 2008():465715. PubMed ID: 18815616
[TBL] [Abstract][Full Text] [Related]
4. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Fu J; Oveisi F; Gaetani S; Lin E; Piomelli D
Neuropharmacology; 2005 Jun; 48(8):1147-53. PubMed ID: 15910890
[TBL] [Abstract][Full Text] [Related]
5. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
Bays HE; Schwartz S; Littlejohn T; Kerzner B; Krauss RM; Karpf DB; Choi YJ; Wang X; Naim S; Roberts BK
J Clin Endocrinol Metab; 2011 Sep; 96(9):2889-97. PubMed ID: 21752880
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation.
Ye JM; Doyle PJ; Iglesias MA; Watson DG; Cooney GJ; Kraegen EW
Diabetes; 2001 Feb; 50(2):411-7. PubMed ID: 11272155
[TBL] [Abstract][Full Text] [Related]
7. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.
Haczeyni F; Wang H; Barn V; Mridha AR; Yeh MM; Haigh WG; Ioannou GN; Choi YJ; McWherter CA; Teoh NC; Farrell GC
Hepatol Commun; 2017 Sep; 1(7):663-674. PubMed ID: 29404484
[TBL] [Abstract][Full Text] [Related]
8. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Huang TH; Peng G; Li GQ; Yamahara J; Roufogalis BD; Li Y
Toxicol Appl Pharmacol; 2006 Feb; 210(3):225-35. PubMed ID: 15975614
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
[TBL] [Abstract][Full Text] [Related]
10. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
11. Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes.
Thangavel N; Bratty MA; Javed SA; Ahsan W; Hazmi HA
J Biol Regul Homeost Agents; 2019; 33(3):707-719. PubMed ID: 31204468
[TBL] [Abstract][Full Text] [Related]
12. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of a novel, non-TZD PPARgamma agonist.
Chen X; Osborne MC; Rybczynski PJ; Zeck R; Yang M; Xu J; Zhou L; Cryan E; Tang Y; Demarest KT
Diabetes Obes Metab; 2005 Sep; 7(5):536-46. PubMed ID: 16050946
[TBL] [Abstract][Full Text] [Related]
14. Citreoviridin induces triglyceride accumulation in hepatocytes through inhibiting PPAR-α in vivo and in vitro.
Feng C; Li D; Jiang L; Liu X; Li Q; Geng C; Sun X; Yang G; Yao X; Chen M
Chem Biol Interact; 2017 Aug; 273():212-218. PubMed ID: 28645467
[TBL] [Abstract][Full Text] [Related]
15. Betaine supplement alleviates hepatic triglyceride accumulation of apolipoprotein E deficient mice via reducing methylation of peroxisomal proliferator-activated receptor alpha promoter.
Wang L; Chen L; Tan Y; Wei J; Chang Y; Jin T; Zhu H
Lipids Health Dis; 2013 Mar; 12():34. PubMed ID: 23497035
[TBL] [Abstract][Full Text] [Related]
16. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
17. mTORC2 Facilitates Liver Regeneration Through Sphingolipid-Induced PPAR-α-Fatty Acid Oxidation.
Zhang L; Li Y; Wang Y; Qiu Y; Mou H; Deng Y; Yao J; Xia Z; Zhang W; Zhu D; Qiu Z; Lu Z; Wang J; Yang Z; Mao G; Chen D; Sun L; Liu L; Ju Z
Cell Mol Gastroenterol Hepatol; 2022; 14(6):1311-1331. PubMed ID: 35931382
[TBL] [Abstract][Full Text] [Related]
18. Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice.
Feng L; Luo H; Xu Z; Yang Z; Du G; Zhang Y; Yu L; Hu K; Zhu W; Tong Q; Chen K; Guo F; Huang C; Li Y
Diabetologia; 2016 Jun; 59(6):1276-86. PubMed ID: 26983922
[TBL] [Abstract][Full Text] [Related]
19. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids.
Huang TH; Peng G; Kota BP; Li GQ; Yamahara J; Roufogalis BD; Li Y
Br J Pharmacol; 2005 Jul; 145(6):767-74. PubMed ID: 15880139
[TBL] [Abstract][Full Text] [Related]
20. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
